AZN Astrazeneca

Filed: 15 Nov 21, 11:28am
Washington, D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of November 2021
Commission File Number: 001-11960
AstraZeneca PLC
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F X Form 40-F __
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes __ No X
If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________
AstraZeneca PLC
1. Director/PDMR Shareholding
15 November 2021 16:00 GMT
Transaction by Person Discharging Managerial Responsibilities
AstraZeneca PLC (the Company) announced that on 12 November 2021 an award of AstraZeneca American Depositary Shares (ADSs) vested to Dr Aradhana Sarin, Chief Financial Officer. Each ADS represents one half of an Ordinary Share of $0.25 in the Company.
In accordance with the Agreement and Plan of Merger, the award was granted under the AstraZeneca Global Restricted Stock Plan at the time of closing of the acquisition of Alexion Pharmaceuticals, Inc. (Alexion) by the Company. It replaced Restricted Stock Units held by Dr Sarin under the Alexion 2017 Incentive Plan, granted in November 2017.  The replacement award vested on the completion of the original four-year holding period.
Following the withholding of shares to satisfy certain tax obligations arising on vesting, 5,108 ADSs vested.
For tax purposes, the fair market value of an ADS at vest of the award was US$62.92, being the closing price on the last trading day preceding the vesting.
Further details are set out in the attached notification, made in accordance with the requirements of the EU Market Abuse Regulation (as it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018.
Details of the person discharging managerial responsibilities / person closely associated
NameAradhana Sarin
Reason for the notification
Chief Financial Officer
Initial notification /AmendmentInitial notification
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
NameAstraZeneca PLC
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
Description of the financial instrument, type of instrument
Identification code
AstraZeneca PLC American Depositary Shares
CUSIP: 046353108
Nature of the transaction
Acquisition of AstraZeneca PLC American Depository Shares pursuant to a vesting under the Global Restricted Stock Plan
Price(s) and volume(s)
Aggregated information
- Aggregated volume
- Price
Not applicable - single transaction
Date of the transaction
12 November 2021
Place of the transaction
Outside a trading venue
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit and follow the Company on Twitter @AstraZeneca.
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 AstraZeneca PLC
Date: 15 November 2021
 By: /s/ Adrian Kemp
 Name: Adrian Kemp
 Title: Company Secretary